Neurocrine Biosciences Surges to 120th in Trading Volume with $609 Million Day

On May 6, 2025, Neurocrine Biosciences (NBIX) experienced a significant surge in trading volume, reaching $609 million, marking a 201.89% increase from the previous day. This substantial rise placed Neurocrine at the 120th position in terms of trading volume for the day. The stock price of Neurocrine also saw a notable increase, rising by 8.36% over the past three days, with a cumulative gain of 11.57%.

Neurocrine Biosciences reported strong financial results for the first quarter of 2025, with INGREZZA achieving net product sales of $545 million. This performance underscores the company's robust market position and the effectiveness of its commercial strategies. The company's leadership highlighted the strong execution across both INGREZZA and CRENESSITY, with record new patient starts for INGREZZA and encouraging early adoption of CRENESSITY. This momentum positions Neurocrine well for both near- and long-term revenue growth.

The company's research and development portfolio continues to advance, with osavampator and NBI-568 progressing into Phase III registrational studies. The positive results from Phase II proof-of-concept studies for these programs have given Neurocrine confidence in continued investment. Additionally, the company is on track to expand its muscarinic portfolio into new Phase II studies later this year, including NBI-568 for bipolar mania and NBI-570 for schizophrenia.

Neurocrine Biosciences maintains a strong financial position with approximately $1.8 billion in cash, supporting future growth and investment. The company has reaffirmed its 2025 financial guidance, with INGREZZA sales expectations set at $2.5 billion to $2.6 billion. Despite a challenging environment, Neurocrine's diversified revenue base, expanding pipeline, and strong balance sheet position it well to continue building on its momentum as a leading global neuroscience company.